Clinical Report: FDA Approval Advances Basal Insulin

Overview

The FDA has approved insulin icodec-abae (Awiqli) as the first once-weekly basal insulin for adults with type 2 diabetes. This innovative treatment reduces the frequency of injections from seven to one per week, demonstrating significant efficacy in glycemic control.

Background

The management of type 2 diabetes often requires multiple daily insulin injections, which can be burdensome for patients. The introduction of a once-weekly basal insulin could enhance adherence to treatment regimens and improve overall glycemic control. This approval represents a significant advancement in diabetes care, particularly for patients struggling with daily insulin administration.

Data Highlights

Key Findings

• Insulin icodec-abae is the first once-weekly basal insulin approved by the FDA.
• The treatment is indicated as an adjunct to diet and exercise for adults with type 2 diabetes.
• It significantly reduces the number of injections from seven to one per week.
• The ONWARDS trials demonstrated efficacy in reducing HbA1c levels compared to daily basal insulin.
• The safety profile of insulin icodec-abae is consistent with that of the daily basal insulin class.

Clinical Implications

Healthcare providers should consider insulin icodec-abae as a viable option for patients with type 2 diabetes who require basal insulin therapy. The reduction in injection frequency may improve patient adherence and overall management of diabetes. Proper patient education on the use of the Awiqli FlexTouch device will be essential for successful implementation.

Conclusion

The approval of insulin icodec-abae marks a significant milestone in diabetes management, offering a new treatment option that simplifies insulin administration for patients with type 2 diabetes. Ongoing monitoring of its clinical use will be important as it becomes available in the market.

References

1. Novo Nordisk, FDA Report, 2026 -- FDA Approval of Insulin Icodec-Abae
2. ADA, Standards of Care, 2026 -- 2026 ADA Standards of Care
3. PubMed, ONWARDS Phase 3a Program -- Weekly Icodec vs Daily Glargine
4. the medicine maker — This Week’s Biopharma News: Wave of Antibody Approvals
5. conexiant — FDA Approves First Generic Versions of FARXIGA
6. The ASCO Post — FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation, Approval of Test for Cervical Cancer, and More
7. The ASCO Post — New Approvals in Breast and Bladder Cancers
8. This Week’s Biopharma News: Wave of Antibody Approvals
9. FDA Approves First Generic Versions of FARXIGA
10. FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation
11. These highlights do not include all the information needed to use Awiqli® safely and effectively. See full prescribing information for Awiqli.Awiqli (insulin icodec-abae) injection, for subcutaneous useInitial U.S. Approval: 2026
12. https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/49/supplement_1/6/standards-of-care-2026.pdf
13. In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA1c vs. daily glargine at 52 wk - PubMed